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Abstract: New three-dimensionally-structured hybrid phospholipid vesicles, able to load clotrimazole
in a high amount (10 mg/mL), were obtained for the first time in this work by significantly
reducing the amount of water (≤10%), which was replaced with a mixture of glycerol and ethanol
(≈90%). A pre-formulation study was carried out to evaluate the effect of both the composition
of the hydrating medium and the concentration of the phospholipid on the physico-chemical
properties of hybrid vesicles. Four different three-dimensionally-structured hybrid vesicles were
selected as ideal systems for the topical application of clotrimazole. An extensive physico-chemical
characterization performed using transmission electron microscopy (TEM), cryogenic transmission
electron microscopy (cryo-TEM), 31P-NMR, and small-angle X-ray scattering (SAXS) displayed the
formation of small, multi-, and unilamellar vesicles very close to each other, and was capable of
forming a three-dimensional network, which stabilized the dispersion. Additionally, the dilution of
the dispersion with water reduced the interactions between vesicles, leading to the formation of single
unilamellar vesicles. The evaluation of the in vitro percutaneous delivery of clotrimazole showed
an improved drug deposition in the skin strata provided by the three-dimensionally-structured
vesicles with respect to the commercial cream (Canesten®) used as a reference. Hybrid vesicles
were highly biocompatible and showed a significant antifungal activity in vitro, greater than the
commercial cream Canesten®. The antimycotic efficacy of formulations was confirmed by the
reduced proliferation of the yeast cells at the site of infection in vivo. In light of these results,
clotrimazole-loaded, three-dimensionally-structured hybrid vesicles appear to be one of the most
innovative and promising formulations for the treatment of candidiasis infections.
Keywords: phospholipid vesicles; clotrimazole; co-solvents; skin delivery; fungal infections;
Candida albicans
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1. Introduction
The skin is the main barrier and defence of our body and, for this reason, it is susceptible to
different infections and inflammations. Fungal infections, especially candidiasis, currently represent a
significant problem for human health worldwide [1]. Moreover, Candida albicans (C. albicans) is able
to penetrate the stratum corneum inducing lesions, which often becomes systemic and occasionally
lethal [2]. Human cutaneous candidiasis is a pustular dermatosis characterized by visible and
microscopic abscesses that are predominantly composed of polymorphonuclear leukocytes. Usually,
the effectiveness of a topical antifungal treatment depends on the ability of the drug to persist in the
skin surface, penetrate through the stratum corneum, and through the C. albicans biofilm’s matrix to
achieve the effective drug concentration levels inside the yeast’s cells [3]. Different types of topical
compounds have been used in the treatment of fungal skin infections. Among the main classes of
antifungal drug, the azoles, which inhibit the fungal cytochrome P450, are the most successful in
clinical use since the late 1960s [4]. Clotrimazole (1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole),
an imidazole derivative, is a widely used drug with a wide spectrum of antifungal activity, particularly
against candidiasis. Clotrimazole is orally administered for the treatment of systemic candidiasis
(pulmonary and disseminated cryptococcosis, and aspergillosis). However, because of its adverse
effects following systemic administration, it is mainly used for the treatment of localized topical
candidiasis. Further, its topical effectiveness seems to be strongly affected by the formulation [5,6],
which may play a key role in ensuring the permanence and promoting the penetration of drugs in
the skin and biofilm’s matrix [7,8]. To reach this goal, during the past few decades, new topical
delivery systems have been explored [9–11]. Amongst them, phospholipid vesicles have evoked a
considerable interest. Their effectiveness in skin delivery was reported for the first time by Mezei
and Gulasekharam in 1980 [12]. In the last two decades, intensive research led to the introduction
of new classes of liposome-like vesicles, capable of improving the performances of conventional
liposomes, such as elastic or ultra-deformable liposomes so called Transfersomes® [13–15]; soft vesicles
containing ethanol (ethosomes) [16–19]; high performant vesicles containing penetration enhancers
(penetration enhancers containing vesicles, PEVs) [20]; vesicles containing high amount of glycerol in
the water phase (glycerosomes) [21–24]; and vesicles immobilized in a network of hyaluronan sodium
salt (hyalurosomes) [25–27]. All these phospholipid vesicles are characterized by the presence of at
least one additive component or a water cosolvent in the formulation and are mainly composed of
phospholipids and not less than 50% of water as a hydrating medium.
To the best of our knowledge, in the present work, for the first time, new phospholipid vesicles
were developed by significantly reducing the amount of water (≤10%) in the mixture used as a
hydrating medium. Instead of water, a mixture of two co-solvents, glycerol and ethanol, was used.
The assembling of phospholipid in a medium with a reduced amount of water was never studied
before, and seems to be peculiar as the obtained dispersion appeared yellow-brown-transparent
and highly viscous [28]. Clotrimazole was stably loaded in high amounts into these hybrid vesicles
and their main physico-chemical characteristics (size, size distribution, and surface charge) were
measured. Morphology and structure were evaluated by using transmission electron microscopy (TEM),
cryogenic transmission electron microscopy (cryo-TEM), 31P nuclear magnetic resonance (31P-NMR),
and small-angle X-ray scattering (SAXS). The topical delivery of clotrimazole containing hybrid vesicles
was studied in vitro using Franz diffusion cells and newborn pig skin. The vesicle biocompatibility
was assessed in vitro using keratinocytes. Further, the effectiveness of clotrimazole-loaded vesicles
against different Candida strains was studied in vitro and in vivo against C. albicans infections on mice.
2. Materials and Methods
2.1. Materials
Lecithin and glycerol were purchased from Galeno (Potenza, Italy). Clotrimazole, ethanol, and all
the other products of analytical grade were purchased from Sigma-Aldrich (Milan, Italy). Cell medium,
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fetal bovine serum, penicillin, streptomycin, and all the other reagents for cell studies were purchased
from Life Technologies Europe (Monza, Italy).
2.2. Vesicle Preparation
Vesicles were prepared using a two-step method avoiding the use of toxic organic solvents. Lecithin
(900 mg) and clotrimazole (100 mg) were left to swell overnight using different hydrating mixtures
(5 mL): glycerol/ethanol/water 59:39:2 (59:2 vesicles); glycerol/ethanol/water 53:37:10 (54:10 vesicles);
glycerol/ethanol/water 69:29:2 (69:2 vesicles) and glycerol/ethanol/water 63:27:10 (63:10 vesicles). After
that time, each dispersion was sonicated (15 cycles 5 sec on and 2 sec off, 13 microns of probe amplitude)
with a high intensity ultrasonic disintegrator (Soniprep 150, MSE Crowley, London, U.K.). Then, a
further aliquot (5 mL) of the appropriate hydrating mixture was added to each dispersion, which was
then sonicated for another 15 cycles (5 sec on and 5 sec off, 13 microns of probe amplitude) to obtain
the three-dimensionally-structured hybrid vesicles. The composition of samples is reported in Table 1.
Empty vesicles were also prepared to evaluate the effect of the drug on vesicle assembling.











59:2 vesicles 90 10 0.59 0.39 0.02
53:10 vesicles 90 10 0.53 0.37 0.10
69:2 vesicles 90 10 0.69 0.29 0.02
63:10 vesicles 90 10 0.63 0.27 0.10
Samples were purified from the non-incorporated clotrimazole by dialysis using dialysis tubing
(Spectra/Por® membranes: 12–14 kDa MW cut-off, 3 nm pore size; Spectrum Laboratories Inc.,
DG Breda, The Netherlands). Each sample (1 mL) was dialyzed for 4 h, under continuous stirring,
against the appropriate glycerol/ethanol/water mixture (2.5 l). The system was maintained at 25 ◦C
and the medium was refreshed every hour to ensure the complete removal of the unentrapped drug.
2.3. Vesicle Characterization
Transmission electron microscopy (TEM) and cryogenic transmission electron microscopy
(cryo-TEM) analyses were used to confirm the vesicle formation and evaluate the morphology.
TEM analyses were performed using a JEM-1010 (Jeol Europe, Paris, France) transmission electron
microscope equipped with a digital camera MegaView III and a Software “AnalySIS,” at an accelerating
voltage of 80 kV. Before the analyses, samples were stained with phosphotungstic acid solution (1%).
Cryo-TEM analyses were performed to evaluate the morphology of vesicles after dilution with
water. A total of 5 µL of the vesicle dispersion were placed on a glow-discharged holey carbon grid,
vitrified using a Vitrobot (FEI Company, Eindhoven, The Netherlands), and analyzed using a Tecnai
F20 TEM (FEI Company) microscope. The sample was observed in a low-dose mode, at 200 kV, and at
a temperature of around −173 ◦C.
A photon correlation spectroscopy method was used to evaluate the average diameter and
polydispersity index (a measure of the size distribution width) by using a Zetasizer nano-ZS (Malvern
Instruments, Worcestershire, U.K.). Samples were backscattered using a helium-neon laser (633 nm) at
an angle of 173◦ and a constant temperature of 25 ◦C. The Zetasizer nano-ZS was also used to measure
the zeta potential by means of the M3-PALS (mixed mode measurement-phase analysis light scattering)
technique, which measures the particle electrophoretic mobility [29]. Just before the size distribution
and zeta potential analyses, the samples (100 µL) were diluted with the hydrating mixture used for the
preparation (10 mL).
The vesicle average size and zeta potential were monitored over 90 days of storage at room
temperature (25 ± 1 ◦C) to evaluate the stability of the samples.
Pharmaceutics 2019, 11, 263 4 of 18
The entrapment efficiency (EE) was calculated as the percentage of the amount of clotrimazole after
dialysis versus that initially used. The clotrimazole concentration was measured using high performance
liquid chromatography (HPLC) after disruption of the vesicles with methanol (1/1000 dilution).
A chromatograph Alliance 2690 (Waters, Milano, Italy) equipped with a photodiode array detector and
a computer integrating apparatus (EmpowerTM 3) was used to measure the amount of clotrimazole.
A Sunfire C18 column (5 µm, 4.6 × 150 mm, Waters) was used for the analysis, which was performed
at 211 nm. A mixture of water, methanol, and acetonitrile (30/5/65 v/v), delivered at a flow rate of
1 mL/min, was used as the mobile phase.
2.4. 31P-NMR Measurements
A Bruker Avance 600 instrument (Bruker, Etlingen, Germany) was used to process the samples
operating at 242.9 MHz to collect 31P-NMR spectra. The spectra were obtained in the presence of a
gated broad band proton decoupling (5 W input power during acquisition time), and accumulated
free inductive decays were obtained from up to 8000 scans. A spectral width of 48,536 Hz, a memory
of 48,536 data points, a 2 s interpulse time, and a 90◦ radio frequency pulse (11 µs) were used with
inverse-gated decoupling 1H. Prior to the Fourier transformation, an exponential multiplication was
applied, resulting in a 100 Hz line broadening.
2.5. Small- and Wide-Angle X-ray Scattering
A modified Kratky compact camera (Hecus MBraun-Graz-Optical Systems, Graz, Austria),
was used to simultaneously measure the small- (SAXS) and wide- (WAXS) angle X-ray scattering.
The instrument used two coupled linear position sensitive detectors (PSD, MBraun, Garching, Germany)
to monitor the s-ranges (s = 2sinθ/λ, 2θ = scattering angle, λ = 1.54 Å). Nickel-filtered Cu Kα X-rays
were generated using a Philips PW3830 X-ray Generator operating at 50 kV and 30 mA. Ag-stearate
(small-angle region, d-spacing at 48.8 Å) and lupolen (wide-angle region, d-spacing at 4.12 Å) were
used as reference materials for the calibration of the position of the detectors. The samples were loaded
in a thin-walled, high-quality quartz capillary (1 mm diameter) held in a steel cuvette, which provided
good thermal contact to the Peltier heating unit. Data analysis was performed with 3D-View v4.1
software (Hecus MBraun, Graz, Austria).
The program GAP (Global Analysis Program) [30,31] was used to analyze the background of
corrected SAXS data, which allowed for retrieving the membrane thickness [dB = 2(zh + 2σh)] from a full
q-range analysis of the SAXS patterns. The parameters zh and σh (position and width of the Gaussian)
were used to describe the electron-dense head group regions within the electron density model.
2.6. In Vitro Skin Delivery Studies
Experiments were performed using new-born pig skin sandwiched between the donor and
receptor compartments of Franz vertical cells with an effective diffusion area of 0.785 cm2. The receptor
compartment was filled with saline (NaCl 0.9% in water), thermostated at 37 ± 1 ◦C, and continuously
stirred. Clotrimazole containing three-dimensionaly-structured hybrid vesicles was applied (100 µL)
onto the skin surface under non-occlusive conditions [32]. Canesten® cream was used as a
reference. The receiving solution was withdrawn at regular intervals (2, 4, 6, and 8 h), replaced
with pre-thermostated (37 ± 1 ◦C) fresh saline solution, and analyzed using HPLC for clotrimazole
content (Section 2.3). At the end of the experiment, the skin surface was gently blotted on filter
paper, and adhesive tape Tesa® AG (Hamburg, Germany) was used to remove the stratum corneum via
stripping. The epidermis was separated from the dermis with a surgical scalpel. Tape strips, epidermis,
and dermis were cut into small pieces to increase the surface contact with methanol and were sonicated
for 2 min in an ice bath to completely extract the drug. The tapes and tissues were filtered out and the
solutions were assayed for drug content using HPLC (see Section 2.3).
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2.7. Cell Viability Assay
Human keratinocytes (HaCaT) (ATCC collection, LCG Standards S.R.L, Sesto San Giovanni,
MI, Italy) were grown as monolayers in 75 cm2 flasks incubated in 100% humidity and 5% CO2
at 37 ◦C. Dulbecco’s Modified Eagle Medium (DMEM) with high glucose, enriched with 10% fetal
bovine serum, penicillin-streptomycin, and fungizone, was used as the growing medium. For the
experiments, cells were seeded in a 96-well plates at a density of 7.5 × 103 cells/well, and after
24 h of incubation, were exposed for 48 h to clotrimazole-loaded hybrid vesicles at different drug
concentrations (2, 10, 20, 50, 100 µg/mL). Cell viability was assessed by adding (100 µL, 0.5 mg/mL) of
MTT [3(4,5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide] to each well. After 3 h, dimethyl
sulfoxide (100 µL in each well) was used to dissolve the formazan crystals, and the absorbance was
read at 570 nm using a microplate reader (Multiskan EX, Thermo Fisher Scientific, Inc., Waltham,
MA, USA). All the experiments were repeated at least three times, each in triplicate. The results are
presented as the percentage of untreated cells (100% viability) [25,33,34].
2.8. In Vitro Antifungal Activity
A clinical Candida albicans multidrug-resistant isolate CA97, was used for the antifungal
susceptibility test. This strain has been previously characterized for its response to different commercial
antifungals and it was shown to be resistant to three different azoles (Fluconazole, Voriconazole,
Ketoconazole) [35]. This clinical isolate has been subsequently evaluated in vitro following the
methodology recommended by the Clinical and Laboratory Standards Institute (CLSI) [36], and it was
shown to be clotrimazole sensitive (data not shown in this manuscript).
The agar diffusion method was performed by using the Kirby–Bauer procedure, used as a
preliminary antimicrobial test to reveal the antifungal susceptibility profile in the formulations [37,38].
Colony forming cells (CFU, 1 × 107/mL) were inoculated onto the surface of a Sabouraud agar plate
and 50 µL of each formulation, corresponding to 500 µg of clotrimazole, was inserted in each well
(Ø10 mm diameter and 2 mm thick) in the centre of the plate [39]. Petri dishes were then incubated in
air at 37 ◦C for 24 h. After incubation, the inhibition diameter was measured. The experiment was
performed in triplicate.
The minimum inhibitory concentration (MIC) and minimum bactericide concentration (MBC)
were measured according to the methodologies recommended by the Clinical Laboratory and Standards
Institute [36]. The experiment has been performed in sterile NuncTM MicrowellTM 96-well microplates
(Thermo Fisher Scientific). Each formulation (200 L) serially diluted (1:2) in Sabouraud dextrose broth
(Microbiol Uta, Cagliari, Italy) from 5 to 2.4 × 10−3 µg/mL of clotrimazole was tested. Suspension of
C. albicans (200 µL, 1 × 106 CFU/mL) diluted in Sabouraud dextrose broth was inoculated into each well
to obtain a final inoculum concentration of 105 CFU/mL. After 48 h at 37 ◦C, the plates were read with
a microplate reader at 620 nm (SLT-Spectra II, SLT Instruments, Crailsheim, Germany). The MIC was
the lowest concentration of an antimicrobial that inhibited the visible growth (absence of turbidity).
To determine the MBC, 100 µL of the dilution representing the MIC and at least two of the more
concentrated tested clotrimazole formulations were plated in Sabouraud agar at 37 ◦C; after 24 h,
the colony-forming units (CFUs) were enumerated. The MBC was the lowest concentration able to
effectively reduce the yeast growth (99.5%).
The ability of clotrimazole-containing, three-dimensionally-structured hybrid vesicles to inhibit
the biofilm formation was evaluated following the crystal-violet staining protocol, as previously
reported [39,40]. Inoculum and the formulation dilution procedures were the same as those already
described for the MIC and MBC experiments. In this context, the minimum biofilm inhibitory
concentration (MBIC) represented the lowest concentration able to interfere with biofilm formation.
In other words, after the C. albicans biofilm staining using crystal violet, the MBIC represented the
concentration of drug able to show an absorbance comparable to the negative control (sample without
bacteria). For each formulation, the experiment was performed in triplicate. For the same concentration,
all data that showed a standard deviation within ±10% of the mean value were considered significant.
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2.9. In Vivo Antifungal Activity
Protocols for the in vivo studies using mice were approved by the Animal Care Committee
of the Faculty of Pharmacy at the University of Valencia (Spain) (reference: 2016/VSC/PEA/00208).
Male 2–3 months old ICR (CD-1) mice, weighing 20–25 g, (Envigo, the provider of standard research
models, Barcelona, Spain), were obtained from the animal facility of the University of Valencia (Faculty
of Pharmacy) and were kept in a clean room at a temperature of 23 ± 1 ◦C, a relative humidity of
60%, and a light/dark cycle of 12 h. A standard laboratory diet was administered to the mice, which
had access to water ad libitum. Prior to fungal infection, mice were immunosuppressed by means of
intraperitoneal injections of cyclophosphamide (100 mg/kg/day) for 3 days [41,42].
A working culture of C. albicans grown for 48 h at 35 ◦C on Sabouraud dextrose agar was used to
prepare a yeast suspension of colony forming units (CFU 107/mL) in a mixture (50/50) of cell culture
medium RPMI 1640 and a yeast extract-peptone-dextrose medium.
Each animal’s back was shaved with an electric clipper on the second day of treatment with
cyclophosphamide. On day 3, the C. albicans (100 µL) suspension was applied on the shaved skin using
a specially designed cylindrical plastic device (4.5 mm i.d. × 6 mm) stuck in the animal’s back with a
cyanoacrylate adhesive to keep the suspension in contact with the skin as long as possible but allowing
aerobic conditions. After 24 h of the inoculation of C. albicans, the infected area was treated with the
different formulations (50 µL): saline (control), Canesten® (reference), and clotrimazole-loaded 59:2
and 63:10 vesicles. All animals were sacrificed after 24 h and the skin around the application area was
excised. The surface of the excised skin was scraped, suspended with 1 mL of Eugon LT 100 broth in an
Eppendorf tube, vortexed for 30 s, and centrifuged (2000× g, 5 min) to collect the pellet containing the
C. albicans. The supernatant was disposed and the pellet was resuspended with an additional volume
of Eugon LT 100 broth (1 mL), vortexed, and centrifuged as indicated. The pellet obtained after the
two washes was resuspended in 1 mL of Eugon LT 100 broth and decimal dilutions were prepared
with the same broth. Each dilution (100 µL) was mixed with 15–20 mL of molten Sabouraud dextrose
chloramphenicol agar in a Petri dish (two dishes for each dilution) and incubated at 35 ◦C for 48–72 h.
The total CFU count of C. albicans on the skin samples was calculated from the number of CFU in
dishes with 30–300 CFU, considering the dilution factor and the volume of dilution in the dishes.
2.10. Microscopic Visualization of Skin Infected with C. albicans
Skin samples of mice inoculated with C. albicans were examined after 24 h using a scanning electron
microscope (SEM, S-4800 Hitachi, Madrid, Spain), and compared with skin samples of untreated
mice to evaluate the effectiveness of the infection. Samples were fixed using a paraformaldehyde and
glutaraldehyde solution (Karnovsky’s Fixative) and dehydrated in a series of ethanol washes (70, 90, 95,
and 100%, v/v). After drying using a critical point method, samples were coated with gold-palladium
prior to microscopic visualization.
2.11. Statistical Data Analysis
Results are expressed as mean ± standard deviation. Statistical differences between groups were
evaluated by using multiple comparison of means (ANOVA), while results between groups were
analyzed by using the Student–Newmans–Keuls method. Significance was tested at the 0.05 level
of probability (p) and data analysis was carried out using the IBM SPSS Statistics v.24 (IBM Corp.,
Armonk, NY, USA) software.
3. Results
3.1. Characterization of Three-Dimensionally-Structured Hybrid Vesicles
Aiming at improving the loading and stability of clotrimazole in phospholipid vesicles,
a pre-formulation study was performed to find an adequate and promising preparation. Phospholipid
vesicles were prepared using different kinds and amounts of phospholipids, and adding surfactants,
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co-solvents, or other additives. The obtained vesicles were unable to retain clotrimazole for more
than one day as it precipitated in a short time irrespective of the composition and the size of the
vesicles. For this reason, for the first time in this work, innovative formulations were developed, which
involved reducing the amount of water usually used as typical hydrating medium of phospholipid
vesicles, and mainly replacing it (≈90%) with a mixture of ethanol and glycerol, thus obtaining
yellow-brown-transparent and viscous dispersions, which avoided the drug precipitation problem for a
long time. Different ratios of glycerol, ethanol, and water were tested, and four mixtures were selected
as they seemed to be the most promising in terms of size distribution and clotrimazole retention
(Table 1). Corresponding empty vesicles were prepared to evaluate the influence of clotrimazole in
vesicle assembling.
Due to the novelty of these formulations, it is important that they were fully characterized. First,
the formation and morphology of vesicles in their native environmental was observed using TEM
(Figure 1, upper panel). The images confirmed the presence of coexisting multi- and single-lamellar
vesicles, characterized by a fairly regular spherical shape, which appeared close-packed and formed a
three-dimensional network [43].
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Figure 1. TEM images (upper panel) of three-dimensionally-structured hybrid 59:2 vesicles (A),
53:10 vesicles (B), 69:2 vesicles(C), and 63:10 vesicles (D). Scale bars represent 100 nm. Cryo-TEM
images (lower panel) of diluted three-dimensionally-structured hybrid 59:2 vesicles (E), 53:10 vesicles
(F), 69:2 vesicles (G), and 63:10 vesicles (H). Scale bars represent 500 nm.
Further, to simulate the behavior that the vesicles may undergo in vivo in the biological
fluids, the samples were di uted (1/500) with water, and i these conditions, it was possible
to freeze the dispersion and observe the by using the cryo-TEM technique. After the
dilution, the three-dimensionally-structured hybrid vesicles became single vesicles, and multi- and
single-lamellar structures coexisted together (Figure 1, lower panel).
The size distribution, zeta potential, and entrapment efficiency of empty and clotrimazole-loaded
hybrid vesicles wer measured (Tabl 2). Empty vesicles were bigger than t e corresponding
clotrimazole-loaded vesicles denoti g the i fluence of the drug in favori g the bil yer assembling,
which resulted in a larger curvature and s aller vesicles. The amount of water was also able to
modify the bilayer assembling, being bigger the vesicles containing the higher amount of water
(53:10 vesicles and 63:10 vesicles, p < 0.05) with respect to the corresponding vesicles containing the
lower amount (59:2 vesicles and 69:2 vesicles). Considering the clotrimazole loaded vesicles, the
mixture glycerol/ethanol/water 59:39:2, containing the lower amount of water, provided the formation
of the smallest vesicles (96 ± 2 nm), while increasing the amount of water (to glycerol/ethanol/water
53:37:10) provided a significant increase in vesicle mean diameter (186 ± 6 nm). The variation of
glycerol and ethanol ratio, reducing the amount of ethanol in favor of that of glycerol (69:29:2 and
63:27:10 ratio), allowed for the formation of vesicles with an intermediate size (≈135 nm), irrespective of
the amount of water used. The zeta potential was highly negative for all the formulations irrespective
of the presence of the drug.
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Table 2. Mean diameter, polydispersity index (PI), zeta potential, and entrapment efficiency (EE) of
empty and clotrimazole-loaded three-dimensionally-structured hybrid vesicles. Mean value ± standard
deviation was obtained from six independent samples.
Mean Diameter (nm) PI Zeta Potential (mV) EE (%)
Empty 59:2 vesicles 171 ± 2 0.38 −55 ± 2 -
Empty 53:10 vesicles 244 ± 13 0.43 −68 ± 3 -
Empty 69:2 vesicles 169 ± 2 0.30 −65 ± 1 -
Empty 63:10 vesicles 221 ± 3 0.38 −66 ± 3 -
Clotrimazole 59:2 vesicles 96 ± 2 0.26 −64 ± 58 96 ± 5
Clotrimazole 53:10 vesicles 186 ± 6 0.29 −59 ± 2 84 ± 5
Clotrimazole 69:2 vesicles 129 ± 7 0.28 −77 ± 1 98 ± 8
Clotrimazole 63:10 vesicles 140 ± 11 0.23 −61 ± 1 81 ± 7
The amount of clotrimazole incorporated in both formulations containing the smaller amount of
water (59:2 and 69:2 vesicles) was slightly higher (≈97%) in comparison with that incorporated in the
formulations containing a higher amount of water (≈83%), probably because both glycerol and ethanol
favored the solubilization of the drug inside the vesicles and in the vesicle bilayer [44].
Vesicle stability was evaluated for 90 days at room temperature (25 ± 1 ◦C, Figure 2). The values
of the checked parameters (mean diameter, polydispersity index, and zeta potential) of 59:2 and
69:2 vesicles remained almost constant over all the storage periods (variation < 10%, p > 0.05), while
53:10 and 63:10 vesicles, containing a higher amount of water, suffered a significant change in size,
as they reached ≈238 nm in diameter in a short time. The presence of water probably reduced the
stability of the vesicles favoring its aggregation or fusion.
Pharmaceutics 2019, 11, x FOR PEER REVIEW 8 of 18 
 
a le 2.  i , l i  i       ffi    
 and clotrimazo e-loa ed three-dime sionally-structured hybr d vesicles. Mean v lue ± 
standard deviation was obtained from six i depend nt samples. 
 Mean Diam ter (nm) PI Zeta Potential ( V) EE (%) 
Empty 59:2 vesicles 171 ± 2 0.38 −55 ± 2 - 
Empty 53:10 vesicles 244 ± 13 0.43 −68 ± 3 - 
Empty 69:2 vesicles 169 ± 2 0.30 −65 ± 1 - 
Empty 63:10 vesicles 221 ± 3 0.38 −66 ± 3 - 
Clotrimazole 59:2 v icles 96 ± 2 0.26 −64 ±  96 ± 5 
Clotrimazole 53:10 v icles 186 ± 6 0.29 −59 ±  84 ± 5 
Clotrimazole 69:2 v icles 129 ± 7 0.28 −77 ±  98 ± 8 
Clotrimazole 63:10 vesicles 140 ± 11 0.23 −61 ± 1 81 ± 7 
The amount of clotrimazole incorporated in both formulations containing the smaller amount of 
water (59:2 and 69:2 vesicles) was slightly higher (≈97%) in comparison with that incorporated in the 
formulations containing a higher amount of water (≈83%), probably because both glycerol and 
ethanol favored the solubilization of the drug inside the vesicles and in the vesicle bilayer [44]. 
Vesicle stability was evaluated for 90 days at room temperature (25 ± 1 °C, Figure 2). The values 
of the checked parameters (mean diameter, polydispersity index, and zeta potential) of 59:2 and 69:2 
vesicles remained almost constant over all the storage periods (variation < 10%, p > 0.05), while 53:10 
and 63:10 vesicles, containing a higher amount of water, suffered a significant change in size, as they 
reached ≈238 nm in diameter in a short time. The presence of water probably reduced the stability of 
the vesicles favoring its aggregation or fusion. 
 
Figure 2. Values of size, polydispersity index (A), and zeta potential (B) of clotrimazole loaded three-
dimensionally-structured hybrid vesicles collected over 90 days of storage at 25 ± 1 °C. Mean values 
± standard deviation (error bars) were reported from six independent samples. 
3.2. 31P-NMR Measurements and Small- and Wide-Angle X-ray Scattering (SAXS and WAXS) 
The 31P-NMR spectra of empty and clotrimazole-loaded three-dimensionally-structured hybrid 
vesicles were collected and compared (Figure 3). 
Figure 2. Values of size, polydispersity index (A), and zeta potential (B) of clotrimazole loaded
three-dimensionally-structured hybrid vesicles collected over 90 days of storage at 25 ± 1 ◦C.
Mean values ± standard deviation (error bars) were reported from six independent samples.
3.2. 31P-NMR Measurements and Small- and Wide-Angle X-ray Scattering (SAXS and WAXS)
The 31P-NMR spectra of empty and clotrimazole-loaded three-dimensionally-structured hybrid
vesicles were collected and compared (Figure 3).
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values were found for empty (6.5 ± 0.1 Å) and clotrimazole-loaded 59:2 vesicles (6.3 ± 0.2 Å), and
empty (6.7 ± 0.1 Å) and clotrimazole-loaded 63:10 vesicles (6.8 ± 0.2 Å), probably due to the high
amount of glycerol and ethanol in the mixture. A substantially lower increase in σH was observed
for empty (4.7 ± 0.2 Å) and clotrimazole-loaded 69:2 vesicles (4.5 ± 0.2 Å), and empty (4.8 ± 0.2 Å)
and clotrimazole-loaded 63:10 vesicles (4.1 ± 0.2 Å). This different behavior may indicate that ethanol
is the main substance responsible for the expansion of the polar group since 59:2 and 53:10 vesicles
contained 39% and 36% of ethanol respectively, while 69:2 and 63:10 vesicles contained 29% and 27%
of ethanol respectively. Results also indicate that glycerol simulated a behavior like that of water.
Table 3. Fitting parameters, σH (polar head amplitude), zH (position of the headgroup Gaussian
of the electron density profile), and dB (bilayer thickness) of empty and clotrimazole-loaded
three-dimensionally-structured hybrid vesicles. Mean values ± standard deviation are reported.
zH σH dB
Empty liposomes 18.7 ± 0.1 3.4 ± 0.1 51.0 ± 0.6
Empty 59:2 vesicles 16.9 ± 0.2 6.5 ± 0.1 59.9 ± 0.8
Empty 53:10 vesicles 16.8 ± 0.2 6.7 ± 0.1 60.4 ± 0.8
Empty 69:2 vesicles 19.0 ± 0.1 4.7 ± 0.2 56.8 ± 1.0
Empty 63:10 vesicles 20.4 ± 0.1 4.8 ± 0.2 60.0 ± 1.0
Clotrimazole 59:2 vesicles 17.7 ± 0.2 6.3 ± 0.2 60.6 ± 1.2
Clotrimazole 53:10 vesicles 17.4 ± 0.2 6.8 ± 0.2 62.0 ± 1.2
Clotrimazole 69:2 vesicles 18.5 ± 0.2 4.5 ± 0.2 55.0 ± 1.2
Clotrimazole 63:10 vesicles 18.9 ± 0.1 4.1 ± 0.2 54.2 ± 1.0
The bilayer thickness (dB) of empty liposomes was 51.0 ± 0.6 Å and those of three-dimensionally-
structured hybrid vesicles were significantly higher (Table 3). This expansion of the bilayer thickness
was a consequence of the presence of the glycerol and ethanol mixture, which played an important
role on vesicle assembly. Indeed, the dB of clotrimazole-loaded 59:2 vesicles was 60.6 ± 1.2 Å and
that of clotrimazole-loaded 53:10 vesicles was 62.0 ± 1.2 Å. Additionally, ethanol seemed to be the
main substance responsible of this bilayer enlargement, and as already found for the increase of σH,
for empty and clotrimazole-loaded 69:2 and 63:10 vesicles, the dB values were slightly smaller than
that of 59:2 and 53:10 vesicles, which contained a higher amount of ethanol.
3.3. In Vitro Skin Permeation Studies
In vitro skin permeation studies displayed the ability of the three-dimensionally-structured hybrid
vesicles to facilitate the accumulation of clotrimazole in the epidermis, especially in the stratum corneum
(Figure 4). The amount of clotrimazole permeated through the skin into the receptor compartment was
very low during the 8 h of experiment as it was not detectable using HPLC.
The commercial cream Canesten® was used as a reference. It is a commercial product containing
clotrimazole (1%) dispersed in a cream composed of sorbitan monostearate, tween 60, cetile palmitate,
cetostearyl alcohol, octyldodecanol, benzyl alcohol, and water. Canesten® allowed for a very low
accumulation of the drug in the different skin strata (≈2%, p < 0.05 versus that provided by all the other
vesicles) to a significantly lesser extent with respect to three-dimensionally-structured hybrid vesicles.
Indeed, when clotrimazole was loaded in hybrid vesicles, its accumulation in the stratum corneum
(≈22%) was 7 times higher than that obtained using the commercial cream, while in the epidermis and
dermis, it was 10 times higher (≈12%). No significant differences were found between the different
hybrid vesicles, so we can hypothesize that all samples, thanks to the affinity of phospholipids toward
the interlamellar matrix of stratum corneum, the moisturizing effect of glycerol and the solubilizing effect
of ethanol, may reduce the skin barrier function, favoring the deposition of the drug in the different
skin layers. On the contrary, the application of the commercial cream for 8 h was unable to effectively
alter the assembling of the lipid matrix of the skin, thus the accumulation of clotrimazole in the different
strata was significantly lower. Further, in the case of the commercial cream, the accumulation of the
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drug in the skin layers was limited by both the barrier effect of the stratum corneum and its partitioning
between the stratum corneum and the vehicle (cream) [46].
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The commercial cream Canesten® was used as a reference. It is a commercial product containing 
clotrimazole (1%) dispersed in a cream composed of sorbitan monostearate, tween 60, cetile 
Fig re . l ti e a ount of clotrimazole accumulated in the stratum corneum (SC), epidermis (EP),
and dermis (D) after 8 h of treatment with the clotrimazole-loaded three-dimensionally-structured
hybrid vesicles or Canesten® cream. Bars represent the mean ± standard deviation (error bars) of at
least six independent experimental determinations.
3.4. In Vitro Cytotoxicity of Clotrimazole Loaded Hybrid Vesicles
The toxicity of the different clotri az le-loaded ve icles was evaluated using keratinocytes
(HaCat) and measuring the cell viability using the MTT assay (Figure 5).
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Figure 5. Cell viability of keratinocytes incubated for 48 h with the clotrimazole-loaded,
three-dimensionally-structured hybrid vesicles. Data are reported as mean values ± standard deviation
of the cell viability expressed as the percentage of the negative control (100% of viability).
Topical formulations must necessarily make contact with the keratinocytes since they are the
main cells of the epidermis and it is important that their topical application do not cause any adverse
effect on these cells. For this reason, in vitro biocompatibility of formulations against keratinocytes
was evaluated. At all tested clotrimazole concentrations (2, 10, 20, 50, 100 µg/mL), cell viability always
ranged from ≈80 to ≈100%. This indicated that the variation of the vehicle used to obtain hybrid
vesicles and the significant reduction of the amount of water did not modify the high and well-known
biocompatibility of phospholipid vesicles [47,48].
3.5. In Vitro Antifungal Susceptibility Test
The results obtained using the Kirby–Bauer procedure displayed a significant amount of activity
from clotrimazole-loaded hybrid vesicles (≈46 cm) and a lower effectiveness provided by Canesten®
(≈35 cm) (Figure 6), while empty vesicles did not exert any efficacy (data not shown).
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Figure 6. In vitro inhibition halo against C. albicans provided by the clotrimazole-containing,
three-dimensionally-structured hybrid vesicles or Canesten® cream. Data are reported as mean
values ± standard deviation (error bars) of six values.
The values of MIC, MBC, and antibiofilm profile were not evaluated for Canesten® cream
since it formed a turbid dispersion, mainly due to the presence of different insoluble functional
components, which interfered with the spectrophotometric measure. The quantitative antimicrobial
determination of clotrimazole-loaded hybrid vesicles indicated a different efficacy as a function of the
vesicle composition. Indeed, clotrimazole-loaded 63:10 vesicles had the lowest values of MIC and MBC
(1.25 µg/mL), followed by clotrimazole-loaded 59:2 vesicles (2.50 µg/mL), while 53:10 and 69:2 vesicles
and all empty vesicles were characterized by higher values (>5 µg/mL) (Table 4).
Table 4. Values of MIC, MBC, and antibiofilm profile provided by clotrimazole-loaded, three-
dimensionally-structured hybrid vesicles or Canesten® cream. Mean values ± standard deviation
are reported. Canesten® values were not evaluated (NE) since it formed a turbid dispersion, which
interfered with the spectrophotometric measurements.
MIC (µg/mL) MBC (µg/mL) MBIC (µg/mL)
Clotrimazole 59:2 vesicles 2.5 2.5 <0.002
Clotrimazole 53:10 vesicles >5 >5 5
Clotrimazole 69:2 vesicles >5 >5 5
Clotrimazole 63:10 vesicles 1.25 1.25 0.004
Canesten® NE NE NE
Empty 59:2 vesicles >5 >5 >5
Empty 53:10 vesicles >5 >5 >5
Empty 69:2 vesicles >5 >5 >5
Empty 63:10 vesicles >5 >5 >5
An antibiofilm assay showed a different and interesting behavior because clotrimazole-loaded 59:2
vesicles provided the highest biofilm inhibition (MBIC≤ 0.002 µg/mL), followed by clotrimazole-loaded
63:10 vesicles (MBIC = 0.004 µg/mL). These values were much lower than that provided by clotrimazole
loaded 53:10 vesicles and 69:2 vesicles (MBIC = 5 µg/mL). On the contrary, empty vesicles were not able
to effectively inhibit both the biofilm and growth of C. albicans (MBIC > 5 µg/mL). Results confirmed the
effectiveness of three-dimensionally-structured hybrid vesicles to promote the ability of clotrimazole
to interfere with the formation of C. albicans biofilm. The outcomes confirmed a great potential of
clotrimazole-loaded, three-dimensionally-structured hybrid vesicles, especially 59:2 and 63:10 vesicles,
in inhibiting the C. albicans biofilm. In addition, results indicate an important role of glycerol in
promoting the effectiveness of clotrimazole in both C. albicans growth and biofilm formation, as the
best results were obtained using 63:10 and 59:2 vesicles containing the intermediate amount of glycerol
(≈0.61 mL).
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3.6. In Vivo Antifungal Activity Evaluation
The antifungal activity of clotrimazole-loaded hybrid vesicles was evaluated in vivo using
mice carrying a dense layer of C. albicans on their dorsal skins. According to the guidelines of the
ethical committee and aiming at reducing the number of used animals, only the two most promising
formulations of clotrimazole-loaded, three-dimensionally-structured hybrid vesicles, which showed
the best features on in vitro tests, were tested in vivo (59:2 and 63:10 vesicles). Saline was used in the
control group (no inhibition of C. albicans growth) and Canesten® cream was employed as a reference
treatment. Clotrimazole vesicles, as well as Canesten® cream, were able to reduce the count of the
colonies of C. albicans (CFU) in comparison with the control group (Figure 7), but the reduction obtained
using clotrimazole-loaded 59:2 and 63:10 vesicles was significantly higher (p < 0.05) than that obtained
with Canesten® cream.
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To further investigate the effective infection of the dorsal skin of mice after treatment with
C. albicans, SE studies were performed (Figure 8).
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Figure 8. Scanning electron microscopy images of skin samples obtained from C. albicans-infected (A,B)
and non-infected (C,D) mice. Images A and C were obtained using a 1100×magnification and B and D
using a 4000×magnification.
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Infected skin showed a large number of yeasts (10–12 microns across) adhering to the skin
(Figure 8A,B), which were not visible in the untreated skin (Figure 8C,D). The images confirmed the
effective proliferation of C. albicans and the resulting infection on the skin.
4. Discussion
The skin is often subjected to different infections, with fungal ones being the most frequent.
They first infect the skin surface and consequently invade the stratum corneum. Therapeutic agents
can be applied to the surface of the skin in the form of creams, lotions, or sprays. They must be
able to easily penetrate the stratum corneum and kill the fungi (fungicidal agents), or at least reduce
their ability to grow or divide (fungistatic agents). Topical treatments represent the first choice to rid
the skin of topical fungi and yeasts. Azoles (i.e., Miconazole, Clotrimazole, and Ketoconazole) are
especially used for the treatment of infections caused by C. albicans; in particular, clotrimazole topical
preparations are generally well-tolerated, even if local irritation has necessitated the withdrawal of
therapy in a few cases [49]. Different studies were carried out, aiming at ameliorating the antifungal
efficacy of clotrimazole after topical application. Soriano et al. [50] formulated a nanoemulsion of
clotrimazole designed as topical and mucosal delivery systems. Despite their good properties in terms
of physico-chemical characteristics and stability behavior, these systems were not able to ameliorate
the permeation parameters, nor the skin-retained amount, but were able to improve the antifungal
activity in comparison with the commercial cream used as reference.
Hashem et al. [51] formulated microemulsions, which showed, when incorporated in a
conventional gel, an improvement (2 or 3 times) of the clotrimazole retention in the skin, as well as of
the antifungal activity, in comparison with commercial cream, probably due to the adhesive properties
of the gel containing the microemulsion.
Akhtar et al. [52] demonstrated the ability of ethosomes modified using Cavamax W7 and
penetration enhancers (PEG 400, isopropylmyristate, or triethanolamine), to improve the permeation
and accumulation of clotrimazole into the skin. The antifungal activity against C. Albicans was
improved as well using the ethosomal formulation. However, to ensure the correct application of the
formulation in the skin, these systems were inserted in a conventional gel of Carbopol.
The insertion of a nanocarier into a structured vehicle, such as cream, ointment, or gel, to ensure
the correct application of the drug in the skin, is a widely used approach. However, it must be taken
into account that the diffusion and accumulation of the drug into the skin may be limited by its
partitioning between the structured vehicle and the stratum corneum, reducing its effectiveness against
topical infections.
To further ameliorate the efficacy of the treatment of the skin infections caused by Candida albicans,
and to avoid the addition of structured vehicles, in this study, for the first time, new phospholipid
vesicles were formulated by using a mixture of glycerol-ethanol with a low water content (≤10%) as
a hydrating medium, leading to the formation of three-dimensionally-structured hybrid and highly
viscous vesicles. Additionally, hybrid vesicles were prepared using an environmentally-friendly,
easily reproducible, and organic solvent-free method. The performed dynamic laser light scattering,
31P-NMR, and SAXS measurements confirmed the formation of lamellar vesicles that were small in
size, where the clotrimazole played a key role in their assembling and features, probably because
it was well-solubilized in both vesicle compartments, i.e., the hydrating medium and phospholipid
bilayer. The combination of TEM and cryo-TEM analysis allowed us to discover the native structure of
dispersions in a three-dimensionally-structured network, which conferred high viscosity and stability
to the system. After dilution in water media simulating the behavior in biological fluids, the network
disappeared, and vesicles became akin to single particles in dispersion without undergoing the
phenomena of breaking or destabilization. We can speculate that their peculiar behavior can facilitate
topical delivery of the payload because the dispersion can be easily applied on the skin, avoiding the
loss of the formulation after application thanks to its highly viscous structured framework. On the
skin’s surface, the dispersion may interact with the components of the stratum corneum and then with
Pharmaceutics 2019, 11, 263 15 of 18
biological fluids undergoing a dilution, which favors the penetration of single vesicles into both the
stratum corneum and biofilm matrix. Moreover, a part of vesicles can fuse within the skin matrix,
modifying its lamellar assembling and perturbing its ordered structure due to the combined action
of phospholipids, glycerol, and ethanol. As confirmation of this mechanism, all hybrid vesicles,
irrespective to the hydrating medium composition, were able to improve the skin accumulation of
clotrimazole to a greater extent than the commercial cream Canesten® used as a reference. In addition,
despite the high amount of ethanol and glycerol used as a hydrating medium, the biocompatibility
was very high (≈90% viability), confirming that the new vehicle used to produce hybrid vesicles did
not modify the low toxicity of phospholipid vesicles. Physico-chemical and technological properties of
hybrid vesicles did not display important differences among the different formulations, irrespective of
the hydrating mixture used.
In contrast, antimicrobial results confirmed the promising properties of all these new hybrid
vesicles as carriers for the treatment of local C. albicans infections, but in particular, showed the specific
activity of 59:2 and 63:10 vesicle formulations against Candida biofilm. These hybrid vesicles contained
an intermediate amount of glycerol (≈0.61 mL) and this concentration seemed to be ideal in modulating
the vesicles’ ability to interfere against biofilm formation at a low concentration. It is well known that
skin candidiasis represents a “biofilm-related disease” and many studies confirmed the poor ability of
azoles to counteract C. albicans infections structured as a biofilm. In this study, clotrimazole loaded
in 59:2 and 63:10 vesicles showed a great ability to counteract C. albicans infections and inhibit the
biofilm formation, thus underlining their promising properties, especially taking into consideration
the increasing resistance of this yeast to traditional antifungal formulations and treatments [53].
The in vitro results were confirmed by those obtained in vivo, which underlined the higher
effectiveness of the selected formulations to reduce the number of the colonies of the yeasts (CFU) in
comparison with the commercial cream Canesten® used as a reference.
5. Conclusions
Overall, results of this study support the design of a new and promising kind of phospholipid
vesicles called three-dimensionally-structured hybrid vesicles due to their original structure in
dispersion, obtained by using a mixture of glycerol and ethanol with a low content of water (≤10%)
as a hydrating medium. These hybrid vesicles were prepared by using an environmentally-friendly
method, avoiding the use of organic solvents or dissipative methodologies. Four different formulations
were obtained by changing the ratio between ethanol, glycerol, and water, which were all highly stable
and able to promote the payload accumulation in the different skin strata and its antifungal activity.
Results underlined that 59:2 and 63:10 hybrid vesicles contained the ideal combination of ethanol and
glycerol that was capable of ensuring the highest protection against C. albicans biofilm formation and
infection resistance. In conclusion, these hybrid vesicles may be considered as promising carriers for
the treatment of topical fungal infections.
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